Scarica l'app Stockscreener
17.44
4.17%
-0.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$18.22
Aprire:
$17.78
Volume 24 ore:
1.27M
Relative Volume:
0.32
Capitalizzazione di mercato:
$12.96B
Reddito:
$220.00K
Utile/perdita netta:
$-746.08M
Rapporto P/E:
-17.31
EPS:
-1.0074
Flusso di cassa netto:
$-211.81M
1 W Prestazione:
-9.20%
1M Prestazione:
-18.53%
6M Prestazione:
-37.42%
1 anno Prestazione:
-12.53%
Intervallo 1D:
$17.40
$18.13
Intervallo di 1 settimana:
$17.40
$19.34
Portata 52W:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.44 | 13.56B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.74 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.07 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.60 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
838.99 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.62 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
What institutional flow reveals about Summit Therapeutics Inc.Swing Trade & Smart Investment Allocation Tips - newser.com
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
Is Summit Therapeutics Inc. showing signs of accumulation2025 Geopolitical Influence & Stepwise Swing Trade Plans - newser.com
What MACD and RSI say about Summit Therapeutics Inc.2025 Short Interest & Accurate Technical Buy Alerts - newser.com
Can Summit Therapeutics Inc. hit a new high this monthJuly 2025 Trends & Community Consensus Picks - newser.com
Is Summit Therapeutics Inc. stock reversal real or fakeMarket Trend Report & Weekly Market Pulse Alerts - newser.com
1 Monster Stock in the Making to Buy and Hold - AOL.com
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
News impact scoring models applied to Summit Therapeutics Inc.Portfolio Value Report & Weekly Hot Stock Watchlists - newser.com
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See - Yahoo Finance
Should you hold or exit Summit Therapeutics Inc. now2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 - Business Wire
Applying sector rotation models to Summit Therapeutics Inc.2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Summit Therapeutics (SMMT) Aims for FDA Nod for Ivonescimab in N - GuruFocus
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - Insider Monkey
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
10 Stocks Under $20 to Buy According to Analysts - Insider Monkey
Summit Therapeutics (SMMT) files for 26.68M share offering by selling stockholders - StreetInsider
Why Wall Street Is Backing These 3 Comeback Stocks - Investing.com
Patterns Watch: Is Summit Therapeutics Inc. stock a safe haven asset2025 Volume Leaders & Weekly High Return Stock Forecasts - fcp.pa.gov.br
Co-CEO & Executive Chairman of Summit Therapeutics Picks Up 2.5% More Stock - simplywall.st
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares - Yahoo Finance
Insider Spends US$262m Buying More Shares In Summit Therapeutics - 富途牛牛
Can Summit Therapeutics Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio charts2025 Price Targets & High Return Stock Watch Alerts - newser.com
Allianz Asset Management GmbH Decreases Stock Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
What margin trends mean for Summit Therapeutics Inc. stock2025 Top Decliners & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br
Summit Therapeutics proves InvestingPro’s Fair Value accuracy with 40% return By Investing.com - Investing.com South Africa
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.37%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):